Paris (France), January 13, 2022 – 6 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, today announced its financial agenda for 2022.

Event Date*
Full-year 2021 results Wednesday, March 30, 2022
Shareholders’ general meeting Thursday, May 12, 2022
Half-year 2022 results Thursday, July 28, 2022


* This preliminary agenda may be modified. Press releases are published after financial markets close.